# A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fasting Conditions in Healthy Adult Volunteers

> **NCT05959486** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 40 (actual)

## Conditions studied

- Gastric or Duodenal Ulcers

## Interventions

- **DRUG:** BR6002A
- **DRUG:** BR6002B
- **DRUG:** BR6002

## Key facts

- **NCT ID:** NCT05959486
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-14
- **Primary completion:** 2023-08-24
- **Final completion:** 2023-08-24
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05959486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05959486, "A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fasting Conditions in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05959486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*